Phase I/II Study of the Deacetylase Inhibitor Panobinostat As maintenance therapy after an allogeneic stem cell transplantation in patients with high-risk MDS or AML: The Panobest-Trial

Bug, Gesine, Burchert, Andreas, Wagner, Eva-Maria, Kroeger, Nicolaus, Jedlickova, Zuzana, Gueller, Saskia, Metzelder, Stephan, Wolf, Andrea, Bader, Peter, Huenecke, Sabine, Serve, Hubert and Ottmann, Oliver ORCID: https://orcid.org/0000-0001-9559-1330 2015. Phase I/II Study of the Deacetylase Inhibitor Panobinostat As maintenance therapy after an allogeneic stem cell transplantation in patients with high-risk MDS or AML: The Panobest-Trial. Blood 126 (23) , 4344.

Full text not available from this repository.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Schools > Medicine
Subjects:	R Medicine > R Medicine (General)
Publisher:	American Society of Hematology
ISSN:	0006-4971
Last Modified:	02 Nov 2022 09:54
URI:	https://orca.cardiff.ac.uk/id/eprint/96748

Actions (repository staff only)

Edit Item